Amit Sohagia, MD received ACG’s Outstanding Poster Presenter Award for TIF 2.0 procedure poster
REDMOND, Wash. – EndoGastric®Solutions today announced the presentation of three posters at the American College of Gastroenterology (ACG) 2018 Annual Scientific Meeting and Postgraduate Course, highlighting the safety and efficacy of Transoral Incisionless Fundoplication (TIF) 2.0 procedure in the treatment of gastroesophageal reflux disease (GERD). TIF 2.0 procedure is a minimally invasive and endoscopic intervention that enables anatomical correction of the gastric valve without incisions or attendant complications associated with laparoscopic surgical fundoplication. The 2018 annual meeting was held October 5 – 10 in Philadelphia, PA.
Amit Sohagia, MD, a gastroenterologist at Easton Hospital, received the ACG’s Outstanding Poster Presenter Award for an abstract titled “Transoral Incisionless Fundoplication: Effectiveness in Improving Typical and Atypical Symptoms of Gastroesophageal Reflux Disease Incompletely Controlled with Medical Therapy.”
Full release: https://bit.ly/2EgQoOZ
Click to Tweet
“With the prevalence of GERD increasing worldwide, a growing number of patients are living with reflux symptoms that reduce their quality of life and increase their risk of cancer,” said Dr. Sohagia. “Patients refractory to medical therapy may benefit from surgical intervention, but traditional invasive procedures are associated with a variety of adverse events. The results of our study add to the robust foundation of data demonstrating that the TIF procedure improves quality of life in patients by effectively addressing both typical and atypical GERD symptoms.”
Dr. Sohagia presented the results of a prospective study conducted in 41 patients with long-standing history of GERD refractory to acid suppressant medications (proton pump inhibitors [PPIs] or histamine antagonists [H2 blockers]) who underwent the TIF procedure. The primary outcome was patient satisfaction as determined by pre- and post-TIF procedure GERD Health Related Quality of Life Questionnaires (GERD-HRQL) and Reflux Symptom Index (RSI) scores, along with the reduction in the use of PPIs or H2 blockers. At median follow up of nine months, significant improvements were reported for GERD-HRQL and RSI and for symptoms of heartburn, dysphagia and regurgitation (p= 0.0001 for all assessments except for dysphagia, which had a p value of 0.006). At short-term follow up, TIF procedure eliminated the need for PPI therapy in the majority of patients. Patients who initiated PPI or H2 blocker therapy after the TIF procedure also had significant improvements in pre- and post-TIF procedure scores on GERD-HRQL and RSI (p = 0.002 and 0.047, respectively).
The two other posters presented at ACG 2018 were:
- “Efficacy and Safety of Trans-Oral Incisionless Fundoplication Performed by Gastroenterologists,” which demonstrated that gastroenterologists trained in TIF procedure can safely perform the procedure in the endoscopy suite. This may save time and healthcare resources by reducing operating room (OR) use. The study also found that TIF procedure performed by gastroenterologists effectively improved HRQL in patients with symptomatic GERD. Presented by Ali Raza, MD1, Marc Catalano, MD1, Erik F. Rahimi, MD1, Hani A Zamil, MD2, Bijun S. Kannadath, MBBS, MS3, Julie Guider, MD1, Reena V. Chokshi, MD4, Brooks D. Cash, MD, FACG1, Todd Wilson, MD1, Erik Wilson, MD1, Nirav Thosani, MD2;1University of Texas Health Science Center at Houston, Houston, TX; 2University of Texas Health Science Center at Houston / McGovern Medical School, Houston, TX; 3University of Arizona College of Medicine, Phoenix, AZ; 4UT Health – McGovern Medical School, Houston, TX
- “Transoral Incisionless Fundoplication in a Patient with Dysphagia from Peptic Stricture,” which showed that TIF procedure can be used to reduce esophageal acid exposure and prevent stricture recurrence in a patient with dysphagia due to recurrent peptic stricture. Presented by Zain Iqbal Memon, DO, David Dicaprio, DO, Patrick Okolo, MD; Northwell Health Lenox Hill Hospital, New York, NY.
“The data presented at ACG 2018 continues to demonstrate that TIF 2.0 procedure is a safe and effective approach to treating GERD in a variety of patient populations and can be performed in the operating room or the endoscopy suite,” said Skip Baldino, President and CEO of EndoGastric Solutions. “These results highlight the clinical benefits that the TIF 2.0 procedure provides to patients and the workflow flexibility that it affords physicians and care centers. We congratulate Dr. Sohagia on receiving the Outstanding Poster Presenter Award, and for his continued efforts to help the GERD patients he serves.”